Caris FOLFIRSTai
Caris FOLFIRSTai™ is the first clinically validated, AI-powered molecular predictor of chemotherapy efficacy for mCRC patients. Caris FOLFIRSTai is included for mCRC cases at no additional cost, increased turnaround time or added specimen requirements.
Navigate mCRC Standard-of-Care Chemotherapy with Caris FOLFIRSTai
Traditionally, FOLFOX or FOLFIRI chemotherapy (in combination with bevacizumab) are considered for firstline
metastatic colorectal cancer (mCRC) treatment, when patients are unable to tolerate FOLFOXIRI. Now
oncologists have an Artificial Intelligence (AI)-based predictor intended to gauge a mCRC patient’s likelihood of
benefit from first-line FOLFOX+BV followed by FOLFIRI+BV versus FOLFIRI+BV followed by FOLFOX+BV treatment.
Caris FOLFIRSTai Validation Data
Using two independent data sets (real-world evidence and Phase III TRIBE2 study data), Caris FOLFIRSTai demonstrated
that the overall survival (OS) of patients treated in a manner consistent with the Caris FOLFIRSTai prediction was 17.5
months longer (71%) than the OS of patients treated counter to the prediction.1
- 412 cases were manually curated cases with real-world evidence (RWE), which includes data acquired from insurance claims records, electronic medical records and death registries.
- 149 cases analyzed retrospectively from the randomized, prospective phase III TRIBE2 study.
| Median Overall Survival | Caris FOLFIRSTai Indicates: | |
|---|---|---|
| FOLFOX+BV 1st→FOLFIRI+BV 2nd (FOLFOX+BV RWE cohort) |
FOLFIRI+BV 1st→FOLFOX+BV 2nd (FOLFIRI+BV RWE cohort) |
|
| OS When Patient Received: FOLFOX+BV 1st→FOLFIRI+BV 2nd (Figure A) |
42.0 Months | 18.7 Months |
| OS When Patient Received: FOLFIRI+BV 1st→FOLFOX+BV 2nd (Figure B) |
24.5 Months | 34.4 Months |
1. Abraham JP, Magee D, Cremolini C, Antoniotti C, Halbert DD, Xiu J, Stafford P, Berry DA, Oberley MJ, Shields AF, Marshall JL, Salem ME, Falcone A, Grothey A, Hall MJ, Venook AP, Lenz HJ, Helmstetter A, Korn WM, Spetzler DB. Clinical validation of a machine-learning derived signature predictive of outcomes from first-line oxaliplatin-based chemotherapy in advanced colorectal cancer. Clin Cancer Res. 2020 Dec 8:clincanres.3286.2020. doi:10.1158/1078-0432.CCR-20-3286. Epub ahead of print. PMID: 33293373.
How it Works
Comprehensive tumor profiling is performed – Caris FOLFIRSTai is included in Caris mCRC orders. State-of-the-art AI is applied to the molecular testing results to identify a unique molecular signature that predicts a mCRC patient’s likelihood of benefit from first-line FOLFOX+BV followed by FOLFIRI+BV, or FOLFIRI+BV followed by FOLFOX+BV treatment.
| mCRC Patients Eligible for First-Line FOLFOX or FOLFIRI Treatment | ||
|---|---|---|
 |
||
 |
||
| Consider FOLFOX+BV First, Followed by FOLFIRI+BV |
Consider FOLFIRI+BV First, Followed by FOLFOX+BV |
Example Caris Report: Caris FOLFIRSTai Result
For illustrative purposes only, not for clinical use. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all available information concerning the patient’s condition.